Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease

Background and Aim FAST score has a good performance for diagnosing the composite of NASH + NAS >= 4 + F >= 2. However, it has not been evaluated in Latin American individuals with nonalcoholic fatty liver disease (NAFLD). We aimed to analyze the performance of the FAST score in a Brazilian NAFLD population. Methods Cross-sectional study was held in >= 18 years NAFLD patients diagnosed by ultrasonography and submitted to liver biopsy (LB). Liver stiffness (LSM) and CAP measurements were performed with FibroScan (R), using M (BMI < 32 kg/m(2)) or XL probes. Area under receiver operating characteristic (AUROC) curves were calculated as well as sensitivity (S), specificity (Spe), positive predictive value (VPP) and negative predictive value (NPV) for the previously established FAST score cut-offs. Results Among 287 patients included (75% female; mean age 55 +/- 10 years), NASH + NAS >= 4 + F >= 2 was reported in 30% of LB. For the FAST cut-off of 0.35, the S and NPV to rule out NASH + NAS >= 4 + F >= 2 were 78.8% and 87.8%, respectively. Regarding the cut-off of 0.67, the Spe and PPV to rule-in NASH + NAS >= 4 + F >= 2 were 89.1%, 61.8%, respectively. The AUROC of FAST for all included patients was 0.78 (95% CI 0.72-0.84) and for those with > 32 kg/m(2) was 0.81 (95% CI 0.74-0.88). Conclusion FAST score has a good performance in a Brazilian NAFLD population, even in patients with higher BMI when the XL probe is adopted. Therefore, FAST can be used as a noninvasive screening tool mainly for excluding the diagnosis of progressive NASH, reducing the number of unnecessary liver biopsies.

Automated summary

The FAST score performs well in a Brazilian NAFLD population, even in patients with higher BMI when the XL probe is used. Thus, FAST can be utilized as a noninvasive screening tool to exclude the diagnosis of progressive NASH, reducing the need for unnecessary liver biopsies.